Report Highlights

U.S. Genetic Engineering Market Overview

The U.S. genetic engineering market is the largest single-country segment globally, accounting for roughly 38% of worldwide revenues in 2024. Its scale is underpinned by an unmatched concentration of NIH-funded research institutions, a mature venture capital ecosystem, and a regulatory architecture that, despite its complexity, provides clearer commercial approval pathways than most peer nations. The market spans therapeutic gene editing, agricultural biotechnology, industrial synthetic biology, and research tools — a breadth that distinguishes it from European or Asian country markets, which tend to concentrate in one or two verticals.

Structurally, the U.S. market is bifurcated between an FDA-regulated therapeutic and diagnostics segment and a USDA-APHIS-regulated agricultural biotech segment, each with distinct approval timelines, compliance costs, and competitive dynamics. Therapeutic gene therapies command significantly higher per-product revenues, while agricultural biotech benefits from streamlined SECURE Rule exemptions introduced in 2020. Research tools — including gene synthesis, CRISPR reagent kits, and viral vector manufacturing — constitute a rapidly growing enabling layer that serves both segments and is increasingly consolidated among a handful of contract development and manufacturing organizations based in the Northeast and California.

Growth Drivers in the U.S. Genetic Engineering Market

Three country-specific drivers underpin accelerated U.S. market growth through 2032. First, the National Institutes of Health allocated USD 2.8 billion toward genomic medicine research in fiscal year 2024, sustaining a pipeline of over 4,000 active Investigational New Drug applications involving genetic modification technologies. This federal funding functions as a de-risk mechanism that lowers private capital entry thresholds and continuously generates licensable intellectual property that commercial entities translate into approved products. The Advanced Research Projects Agency for Health (ARPA-H) added a further USD 300 million specifically targeting nucleic acid delivery platform development in 2024.

Second, the U.S. demographic profile — with an estimated 30 million Americans living with rare genetic diseases — creates a structurally large addressable patient population for somatic gene therapies. The Orphan Drug Act provides seven-year market exclusivity and substantial tax credits, making rare-disease gene therapy commercially rational in the U.S. even for small-volume indications that would be unviable elsewhere. Third, the USDA SECURE Rule, finalized in 2020, exempts gene-edited crops that could have been produced through conventional breeding from full regulatory review, dramatically compressing the field-to-market timeline for agricultural biotech entrants targeting U.S. commodity and specialty crop sectors.

Market Restraints and Entry Barriers

The FDA's Center for Biologics Evaluation and Research applies rigorous long-term safety monitoring requirements to gene therapy products, including mandatory 15-year patient follow-up under 21 CFR Part 312. This creates a structural financing burden that disadvantages smaller entrants without deep capital reserves or large-pharma partnership arrangements. Manufacturing scalability remains a parallel bottleneck: good manufacturing practice-compliant viral vector production capacity in the U.S. is concentrated among fewer than 20 facilities, creating supply constraints that inflate CDMO contract prices and extend lead times to 18–24 months for clinical-stage programs seeking scale-up.

In agricultural biotech, incumbent advantage is substantial. Corteva Agriscience, Bayer Crop Science, and Syngenta collectively control the majority of proprietary germplasm libraries required to insert edited traits into commercially relevant seed varieties. New entrants without licensing agreements to elite germplasm face a de facto commercialization barrier even after achieving USDA regulatory clearance. Additionally, public perception risks — amplified by organized opposition in specific U.S. state markets, including ballot initiatives in California and Oregon targeting GMO labeling — add non-regulatory entry friction that requires dedicated stakeholder engagement investment before commercial launch.

Market Opportunities in the U.S. Genetic Engineering Market

The in vivo gene editing segment represents the most compelling near-term entry opportunity, with analysts estimating the addressable U.S. market for liver-targeted and CNS gene therapies at USD 6.2 billion by 2028. Intellia Therapeutics' NTLA-2001 program for transthyretin amyloidosis and Wave Life Sciences' stereopure nucleic acid platform signal that non-viral delivery mechanisms are closing the efficacy gap with AAV vectors, opening the market to entrants without legacy AAV manufacturing infrastructure. Partnerships with academic medical centers — particularly those in the NIH-supported Somatic Cell Genome Editing Consortium — provide pre-validated clinical sites that accelerate enrollment timelines.

In the synthetic biology and industrial biotech segment, the U.S. Department of Energy's Bioenergy Technologies Office directed USD 178 million in 2024 toward metabolic engineering of microbial chassis for biofuel and biochemical production. Companies engineering Pseudomonas putida or Corynebacterium glutamicum for specialty chemical biosynthesis face a relatively uncongested competitive field compared to therapeutic gene editing, with faster regulatory clearance under EPA's Toxic Substances Control Act biotechnology review. The domestic biomanufacturing priority established under Executive Order 14081 creates procurement preferences and loan guarantee access that meaningfully lower entry costs for companies establishing U.S.-based biological production facilities targeting federal contracts.

Market at a Glance

Leading Market Participants

• Regeneron Pharmaceuticals
• Moderna
• CRISPR Therapeutics
• Intellia Therapeutics
• Beam Therapeutics
• Corteva Agriscience
• Bayer Crop Science (U.S. Operations)
• Ginkgo Bioworks
• Editas Medicine
• Inari Agriculture

Regulatory and Policy Environment

Gene therapy products in the U.S. are regulated under FDA's Center for Biologics Evaluation and Research, with the primary statutory basis found in Section 351 of the Public Health Service Act and 21 CFR Parts 210, 211, and 600–680. The FDA's 2020 suite of gene therapy guidance documents — including "Human Gene Therapy for Rare Diseases" and "Chemistry, Manufacturing, and Controls Information" — established the current pre-BLA expectations for vector characterization and potency assays. The Regenerative Medicine Advanced Therapy designation, available under the 21st Century Cures Act, provides rolling review and more frequent FDA interactions for qualifying gene therapies, reducing median review timelines by an estimated eight months relative to standard biologics review.

Agricultural genetic engineering is governed by USDA-APHIS under the Coordinated Framework for Regulation of Biotechnology, with the SECURE Rule (7 CFR Part 340, effective 2020) exempting certain gene-edited plants from mandatory regulatory review when edits fall within species-transferable genetic changes. The EPA regulates plant-incorporated protectants under FIFRA, applying separately to herbicide-tolerance and insect-resistance traits. Executive Order 14081, signed September 2022, established the National Biotechnology and Biomanufacturing Initiative, directing USD 2 billion across agencies toward domestic biotech capacity — including BARDA funding for pandemic-relevant gene therapy manufacturing infrastructure and USDA competitive grants targeting precision fermentation and bioengineered crop commercialization.

Long-Term Outlook for the U.S. Genetic Engineering Market

By 2032, the U.S. genetic engineering market is forecast to reach USD 28.7 billion, with therapeutic gene editing commanding the largest share as multiple curative gene therapies move from launch to standard-of-care status across hemoglobinopathies, inherited blindness, and select neurodegenerative indications. The approval and commercial scaling of Casgevy establishes the pricing precedent and reimbursement negotiation model — including outcomes-based contracts with Medicaid — that subsequent gene therapy entrants will inherit. Delivery technology convergence, particularly lipid nanoparticle platforms applicable to both mRNA and DNA cargo, will compress the distinction between gene therapy and advanced biologic, expanding the addressable market definition.

Agricultural biotech will see accelerating trait commercialization under the SECURE Rule, with yield-enhancing and climate-resilient edited varieties from companies including Pairwise Plants and Benson Hill reaching broader U.S. acreage by 2030. Industrial synthetic biology, anchored by large-scale U.S. biofoundry investment at Ginkgo Bioworks and Zymergen-legacy infrastructure, will expand genetic engineering revenues beyond healthcare and food into specialty chemicals, biomaterials, and defense biosecurity applications. The primary risk to this trajectory is congressional reauthorization uncertainty around NIH appropriations and potential FDA policy shifts affecting cell and gene therapy manufacturing standards, either of which could defer commercialization timelines for pipeline-dependent smaller participants.